RESUMO
The variations in average particle size, zeta potential, free fatty acids (FFA) release rate, and the bioavailability of menthol under in vitro simulated digestion conditions of peppermint oil nanoemulsion were investigated. 3D confocal laser scanning microscopy and Cryo-scanning electron microscopy were used to observe the microstructure characteristics of peppermint oil nanoemulsion, which indicated that soybean protein was completely adsorbed at the oil-water interface of the nanoemulsion and presented a core shell structure. And the results indicated that FFA release rate and menthol bioavailability of peppermint oil nanoemulsion prepared by using high-pressure homogenization were much higher. In the simulated gastric digestion phase, the average particle size and the zeta potential of the nanoemulsion increased, and droplet polymerization appeared. After the simulated intestinal, the interfacial protein of nanoemulsion was hydrolyzed, and the oil droplets were digested, which resulted in the decreased particle size and increased absolute value of zeta potential.
Assuntos
Emulsões/química , Nanopartículas/química , Óleos de Plantas/química , Disponibilidade Biológica , Liberação Controlada de Fármacos , Mentha piperita/química , Mentol/farmacocinética , Nanopartículas/ultraestrutura , Tamanho da Partícula , Proteínas de Soja/química , Glycine max/químicaRESUMO
OBJECTIVES: We conducted a randomized, placebo-controlled trial, which evaluated a novel formulation of caraway oil and L-menthol using microsphere-based site-specific targeting (COLM-SST) vs placebo in patients with functional dyspepsia (FD). METHODS: Adult men and women with FD defined by Rome III criteria were recruited. Patients were randomized to COLM-SST (25 mg of caraway oil and 20.75 mg of L-menthol per capsule, at 2 capsules per dose, twice per day) or placebo. Efficacy was measured at 24 hours, 2 weeks, and 4 weeks. Patients were allowed to take concomitant medications for their FD throughout the trial, and rescue medicines were allowed, 48 hours after start of dosing. RESULTS: Ninety-five patients were enrolled (mean age = 43.4 years; 75.8% women). At 24 hours, the active arm reported a statistically significant reduction in postprandial distress syndrome symptoms (P = 0.039), and a nonsignificant trend toward benefit of epigastric pain syndrome symptoms (P = 0.074). In patients with more severe symptoms, approximately 3 quarters of patients showed substantial global improvement (i.e., clinical global impressions), after 4 weeks of treatment, vs half in the control arm. These differences were statistically significant for patients with epigastric pain syndrome (P = 0.046), and trending toward significance for patients with postprandial distress syndrome (P = 0.091). There was no statistically significant difference between groups for Global Overall Symptom scores for the overall population at 2 and 4 weeks. Treatment emergent adverse events were mild to moderate, and no serious adverse events were reported. DISCUSSION: In patients taking their usual medications for FD, COLM-SST provided rapid relief (within 24 hours) and relief of severe FD symptoms. It was safe and well tolerated.
Assuntos
Sistemas de Liberação de Medicamentos/métodos , Dispepsia/tratamento farmacológico , Mentol/administração & dosagem , Óleos de Plantas/administração & dosagem , Adolescente , Adulto , Idoso , Combinação de Medicamentos , Liberação Controlada de Fármacos , Duodeno/metabolismo , Dispepsia/diagnóstico , Feminino , Humanos , Mucosa Intestinal/metabolismo , Masculino , Mentol/efeitos adversos , Mentol/farmacocinética , Microesferas , Pessoa de Meia-Idade , Óleos de Plantas/efeitos adversos , Óleos de Plantas/farmacologia , Período Pós-Prandial , Índice de Gravidade de Doença , Resultado do Tratamento , Adulto JovemRESUMO
INTRODUCTION: Peppermint oil (PO) has been shown to reduce abdominal pain in patients with irritable bowel syndrome (IBS). PO is assumed to induce intestinal smooth muscle relaxation and desensitization of nociceptive nerve afferents. To increase colonic PO concentration, an ileocolonic release peppermint oil (IC-PO) capsule has been developed. The aim of this study was to compare pharmacokinetic parameters of the currently available small intestinal release PO (SI-PO) and the novel IC-PO. METHODS: In this randomized, double-blind, crossover study, subjects received 182 mg of either SI-PO or IC-PO in a crossover design with a washout period of more than 14 days. Blood samples were collected to determine menthol glucuronide concentrations. RESULTS: Eight healthy volunteers (50% female, median age 22) were included. The time to reach the maximum concentration (Tmax) of IC-PO was significantly longer compared to SI-PO with a median (IQR) of 360 (360-405) versus 180 (120-180) min. The lag time (Tlag) was significantly longer with a median (IQR) of 225 (204-284) for IC-PO compared to 37 (6-65) min for SI-PO. The areas under the menthol glucuronide plasma concentration-time curves were significantly smaller with a median (IQR) of 2331 µg h/L (2006-2510) for IC-PO compared to 2623 µg h/L (2471-2920) for SI-PO. No significant differences were found in peak concentrations and elimination half-lives. CONCLUSION: IC-PO has a significantly delayed peak menthol glucuronide concentration and Tlag, both pointing to the release of PO in the more distal part of the intestine. This may enhance therapeutic efficacy as it results in increased exposure of colonic mucosal afferents to the PO. A randomized controlled trial investigating the efficacy of SI and IC-PO in IBS is currently ongoing. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02291445, EudraCT database 2014-004195-32.
Assuntos
Dor Abdominal , Glucuronatos , Síndrome do Intestino Irritável , Mentol/análogos & derivados , Músculo Liso/efeitos dos fármacos , Óleos de Plantas , Dor Abdominal/tratamento farmacológico , Dor Abdominal/etiologia , Adulto , Disponibilidade Biológica , Cápsulas , Estudos Cross-Over , Método Duplo-Cego , Feminino , Glucuronatos/sangue , Glucuronatos/farmacocinética , Voluntários Saudáveis , Humanos , Síndrome do Intestino Irritável/tratamento farmacológico , Síndrome do Intestino Irritável/fisiopatologia , Masculino , Mentha piperita , Mentol/sangue , Mentol/farmacocinética , Parassimpatolíticos/administração & dosagem , Parassimpatolíticos/farmacocinética , Óleos de Plantas/administração & dosagem , Óleos de Plantas/farmacocinéticaRESUMO
BACKGROUND: Ethosomes, a novel type of percutaneous drug delivery carrier with a lipid bilayer structure, penetrate the skin barrier due to their deformability and malleability, and presence of ethanol that fluidizes lipids in the skin. In order to further enhance the delivery of drugs through the skin, penetration enhancers are widely used. OBJECTIVE: The objective of this work was to develop an optimized formulation of lornoxicam ethosomal gels, investigate skin permeability with the addition of penetration enhancers, and evaluate the invivo pharmacodynamics of these formulations. METHODS: Lornoxicam ethosomes were prepared by the ethanol injection method and optimized using the orthogonal design method. Lornoxicam ethosomal gels with enhancers were prepared and optimized using in-vitro transdermal delivery experiments. Experiments on lornoxicam ethosomal gels containing various enhancers such as azone, menthol, lauryl alcohol, and oleic acid were conducted using vertical Franz diffusion cells to measure the percutaneous permeability of the different formulations. Furthermore, the in-vivo analgesic effects of the optimized lornoxicam ethosomal gels were examined using the hot-plate and acetic acid-induced writhing tests. Anti-inflammatory activity was investigated using the dimethylbenzene-induced mouse ear swelling method. RESULTS: The results showed that compared to other formulations, the optimized lornoxicam ethosomal gels with 5 % menthol significantly increased transdermal penetration. Meanwhile, the optimized lornoxicam ethosomal gels showed remarkably anti-nociceptive and anti-inflammatory activity compared with the plain lornoxicam gels. CONCLUSION: These results suggest that the optimized ethosomal gel formulated in this study is a promising lornoxicam carrier in transdermal delivery systems to enhance anti-nociceptive and antiinflammatory efficiency.
Assuntos
Analgésicos/administração & dosagem , Anti-Inflamatórios não Esteroides/administração & dosagem , Mentol/administração & dosagem , Piroxicam/análogos & derivados , Ácido Acético , Analgésicos/química , Analgésicos/farmacocinética , Analgésicos/uso terapêutico , Animais , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/farmacocinética , Anti-Inflamatórios não Esteroides/uso terapêutico , Colesterol/química , Composição de Medicamentos , Sistemas de Liberação de Medicamentos , Edema/induzido quimicamente , Edema/tratamento farmacológico , Etanol/química , Feminino , Géis , Temperatura Alta/efeitos adversos , Lecitinas/química , Lipossomos , Mentol/química , Mentol/farmacocinética , Mentol/uso terapêutico , Camundongos Endogâmicos BALB C , Dor/tratamento farmacológico , Dor/etiologia , Piroxicam/administração & dosagem , Piroxicam/química , Piroxicam/farmacocinética , Piroxicam/uso terapêutico , Absorção Cutânea , XilenosRESUMO
In this work, microemulsion-based gels were prepared for transdermal delivery of paeonol. Microemulsions containing eutectic mixtures of paeonol and menthol were developed. The obtained microemulsions were evaluated for particle size, viscosity and physical stability. The selected microemulsions were incorporated into Carbopol gels. Drug crystallization behavior during a short-term storage was compared and in vitro permeation and deposition study were conducted on mouse skin. Results showed that the eutectic liquids of paeonol and menthol at all ratio (6:4, 5:5 and 4:6) could form microemulsions but with significantly different physical characteristics. As the ratio of paeonol increased, the prepared microemulsions exhibited larger droplet size, higher viscosity and quicker crystal growth. Microemulsion containing paeonol and menthol at a ratio of 4:6 possessed the smallest size of 27 nm. Accordingly, the related gel showed better physical stability during 10 days of storage, as well as the highest percent of drug deposition (111.8 µg/cm2) and steady-state flux (0.3 µg/cm2 h). These results suggested that the microemulsion formulation is a preferable approach for enhanced skin permeation, and the microemulsion based on drug-menthol eutectic mixture might be used as a potential transdermal delivery system for better therapeutic efficacy.
Assuntos
Acetofenonas , Sistemas de Liberação de Medicamentos/métodos , Mentol , Acetofenonas/química , Acetofenonas/farmacocinética , Acetofenonas/farmacologia , Administração Cutânea , Animais , Avaliação Pré-Clínica de Medicamentos , Emulsões , Mentol/química , Mentol/farmacocinética , Mentol/farmacologia , CamundongosRESUMO
Despite its high efficacy in anti-tuberculosis therapy, the oral administration of isoniazid (INH) may lead to poor patient compliance due to hepatotoxicity events. In this context, the transdermal administration of INH was evaluated, for the first time, since this route avoids hepatic first pass effect. INH was applied to porcine skin in Franz diffusion chambers alone and with 5% menthol, limonene or Transcutol(®). Infrared and DSC analyses were selected for mechanistic studies. The transdermal absorption of INH was sufficient to ensure a systemic therapeutic effect. Menthol was not able to improve the absorption of INH, but it increased the drug accumulation in skin compared to the control (1.4-fold). Transcutol(®) reduced permeation flux of INH (2.2-fold) and also increased the amount of drug retained in skin (1.7-fold). Limonene was the most effective excipient since it increased permeation flux of INH (1.5-fold) and lag time was greatly shortened (2.8-fold). DSC and FTIR analyses of limonene-treated skin suggest higher degree of disorder in lipid bilayers. Transdermal delivery of INH was positively correlated with logP of chemical enhancers. INH can be efficiently delivered by skin route and specific excipients may be selected depending on intended use.
Assuntos
Isoniazida/administração & dosagem , Isoniazida/farmacocinética , Absorção Cutânea/efeitos dos fármacos , Administração Cutânea , Animais , Varredura Diferencial de Calorimetria , Cicloexenos/administração & dosagem , Cicloexenos/farmacocinética , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/farmacocinética , Etilenoglicóis/administração & dosagem , Etilenoglicóis/farmacocinética , Excipientes/administração & dosagem , Excipientes/farmacocinética , Limoneno , Mentol/administração & dosagem , Mentol/farmacocinética , Espectroscopia de Infravermelho com Transformada de Fourier , Suínos , Terpenos/administração & dosagem , Terpenos/farmacocinética , Fatores de TempoRESUMO
To determine the concentration of menthol in rat plasma by GC. Rats were administered with single dose of Zhike Chuanbei Pipa dropping pills (ZCPDP) and different doses of menthol herbs. DAS 3. 1.6 software was used to calculate pharmacokinetic parameters, and the accumulative absorption percentage of menthol was calculated by Loo-Riegelman method. The linear regression analysis was made in vitro/in vivo accumulative absorption percentages to detect the in vitro/in vivo correlation. The results of the study showed that the pharmacokinetics behavior of menthol in ZCPDP was in conformity with two-compartment model characteristics. The main parameters were: tmax was 10 min, t1/2beta was (183. 93 52. 75) min, CL/F was (0. 426 +/- 0. 194) L . min-1 . kg-1, all of which were no difference between ZCPDP and menthol herbs with the same dosage. There were significant differences in tmax, t1/2beta, CL/F between menthol herbs with different dosages (P <0. 05) , with indirect proportion between AUC0-infinity and dosage. The regression equation of ZCPDP's accumulative absorption percentage and accumulative release percentage was Fa = 1. 160 3Q - 19. 968, r = 0. 981 3. These results suggested that the pharmacokinetics behavior was similar between ZCPDP and menthol herbs with the same dosage in rats, with good in vitro/in vivo correlation. There were significant differences in pharmacokinetics of menthol in the range of 19.2-570 mg . kg-1.
Assuntos
Medicamentos de Ervas Chinesas/farmacocinética , Mentol/farmacocinética , Animais , Antitussígenos/farmacocinética , Cromatografia Gasosa , Masculino , RatosRESUMO
Menthol is one of the most commonly used chemicals in our daily life, not only because of its fresh flavor and cooling feeling but also because of its medical benefit. Previous studies have suggested that menthol produces analgesic action in acute and neuropathic pain through peripheral mechanisms. However, the central actions and mechanisms of menthol remain unclear. Here, we report that menthol has direct effects on the spinal cord. Menthol decreased both ipsilateral and contralateral pain hypersensitivity induced by complete Freund's adjuvant in a dose-dependent manner. Menthol also reduced both first and second phases of formalin-induced spontaneous nocifensive behavior. We then identified the potential central mechanisms underlying the analgesic effect of menthol. In cultured dorsal horn neurons, menthol induced inward and outward currents in a dose-dependent manner. The menthol-activated current was mediated by Cl(-) and blocked by bicuculline, suggesting that menthol activates γ-aminobutyric acid type A receptors. In addition, menthol blocked voltage-gated sodium channels and voltage-gated calcium channels in a voltage-, state-, and use-dependent manner. Furthermore, menthol reduced repetitive firing and action potential amplitude, decreased neuronal excitability, and blocked spontaneous synaptic transmission of cultured superficial dorsal horn neurons. Liquid chromatography/tandem mass spectrometry analysis of brain menthol levels indicated that menthol was rapidly concentrated in the brain when administered systemically. Our results indicate that menthol produces its central analgesic action on inflammatory pain probably via the blockage of voltage-gated Na(+) and Ca(2+) channels. These data provide molecular and cellular mechanisms by which menthol decreases neuronal excitability, therefore contributing to menthol-induced central analgesia.
Assuntos
Analgesia/métodos , Bloqueadores dos Canais de Cálcio/uso terapêutico , Mentol/uso terapêutico , Neuralgia/tratamento farmacológico , Limiar da Dor/efeitos dos fármacos , Bloqueadores do Canal de Sódio Disparado por Voltagem/uso terapêutico , Potenciais de Ação/efeitos dos fármacos , Animais , Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Bloqueadores dos Canais de Cálcio/farmacocinética , Bloqueadores dos Canais de Cálcio/farmacologia , Canais de Cálcio/metabolismo , Células Cultivadas , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Agonistas de Receptores de GABA-A/farmacologia , Agonistas de Receptores de GABA-A/uso terapêutico , Masculino , Espectrometria de Massas , Mentol/farmacocinética , Mentol/farmacologia , Camundongos , Camundongos Endogâmicos , Neuralgia/metabolismo , Neuralgia/psicologia , Medição da Dor , Limiar da Dor/psicologia , Células do Corno Posterior/efeitos dos fármacos , Células do Corno Posterior/metabolismo , Receptores de GABA-A/metabolismo , Bloqueadores do Canal de Sódio Disparado por Voltagem/farmacocinética , Bloqueadores do Canal de Sódio Disparado por Voltagem/farmacologia , Canais de Sódio Disparados por Voltagem/metabolismoRESUMO
Both borneol and menthol are bioactive substances derived from Chinese herbal medicines. In order to understand the pharmacokinetics of borneol and menthol in Qingyan drop pills, a rapid, sensitive, and simple gas chromatographic (GC) method with flame ionization detection (FID) was developed for the simultaneous determination of borneol and menthol in rat plasma. Sample preparations were carried out by liquid-liquid extraction (LLE) with an internal standard solution of naphthalene. The analytes and internal standard (IS, naphthalene) were separated well on an HP-1 capillary column. The pharmacokinetic parameters were estimated by a compartmental method using the Phoenix WinNonlin software program (Version 6.0). The standard curves were linear over a wide concentration range of 2.5-50.0 ng/µL ( R = 0.9963), 8.7-62.2 ng/µL ( R = 0.9994) for both borneol and menthol in plasma, respectively. The limits of quantification (LOQ) of borneol and menthol in plasma were 2.4 ng/µL and 5.0 ng/µL, respectively. The intra-day precisions for borneol and menthol were < or = 10.0â% R.âS.âD. at the LOQ and < or = 6.0â% at higher concentrations. The average value of CMAX was 18.97 ± 2.71 ng/µL with a TMAX at 20.00 ± 0.00 min for borneol after oral administration of the drop pills; for menthol, the average value of CMAX was 79.02 ± 11.40 ng/µL with a TMAX at 25.00 ± 4.40 min. This validated assay method was successfully applied to a pharmacokinetic study of borneol and menthol after oral administration of Qingyan drop pills in rat. The results showed that the kinetics of borneol and menthol can be described by an open one-compartment model. The pharmacokinetic parameters provide some information for clinical administration of Qingyan drop pills.
Assuntos
Antipruriginosos/farmacocinética , Canfanos/farmacocinética , Medicamentos de Ervas Chinesas/farmacocinética , Mentol/farmacocinética , Administração Oral , Animais , Antipruriginosos/sangue , Canfanos/sangue , Extração Líquido-Líquido , Masculino , Medicina Tradicional Chinesa , Mentol/sangue , Ratos , Padrões de Referência , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
A randomized, two-way, crossover, bioequivalence study in 6 beagle dogs was conducted to compare the bioavailability of two peppermint oil formulations, soft capsule and hard capsule. The drug was given in a single dose of two capsules (total, 200 mg), and blood samples were withdrawn during the 12 h after drug administration. Menthol (CAS 2216-51-5) as the main component of peppermint oil was determined by a gas chromatography-tandem mass spectrometry (GC-MS/I MS) method after cleavage with beta-glucuronidase. The following pharmacokinetic variables were computed for the two formulations: maximum concentration (Cmax), time to maximum concentration (Tmax), half-life of elimination (t1/2), mean residence time (MRT), and areas under the plasma concentration-time curve (AUC(0-t) and AUC(0-infinity)). For calculation of the 90% confidence interval (CI), an analysis of variance (ANOVA) was carried out. The results indicated that treatment and subject had statistically significant effect on AUC(0-t), AUC(0-infinity), and Cmax, and the 90% CIs for AUC(0-t), AUC(0-infinity), and Cmax were outside the acceptable bioequivalence range. The relative bioavailability was 121.4 +/- 10.6% for AUC(0-infinity). Therefore, it can be concluded that the two formulations are not bioequivalent and the bioavailability of soft capsules is significantly higher than that of hard capsules.
Assuntos
Mentol/farmacocinética , Óleos de Plantas/farmacocinética , Administração Oral , Animais , Área Sob a Curva , Disponibilidade Biológica , Cápsulas , Cromatografia Líquida de Alta Pressão , Cães , Feminino , Cromatografia Gasosa-Espectrometria de Massas , Glucuronidase/metabolismo , Meia-Vida , Masculino , Espectrometria de Massas , Mentha piperita , Mentol/administração & dosagem , Mentol/efeitos adversos , Óleos de Plantas/administração & dosagem , Óleos de Plantas/efeitos adversos , Reprodutibilidade dos Testes , Equivalência TerapêuticaRESUMO
The terpenes camphor and menthol are often used in topical preparations, although some data indicate concern about their skin penetration after application in most commonly used vehicles. The cutaneous disposition of these substances applied alone and together in either an oily solution or a hydrogel was evaluated ex vivo using full human skin mounted in flow-through diffusion cells. After 0.5, 1 and 2 h of application, the skin was progressively tape-stripped into three fractions of stratum corneum (SC) and the remaining epidermis with the dermis. The content of terpenes in the skin layers was determined using gas chromatography. Different penetration into the skin layers was observed depending on the type of vehicle. The highest SC absorption was noted when terpenes were applied in hydrogel, where the total content in the SC was 200 microg/cm2 for camphor and 400 microg/cm2 for menthol, and the total skin absorption was 310 and 460 microg/cm2, respectively. The SC penetration of both terpenes from the oily solution was the same (approximately equal to 35 microg/cm2). When both terpenes were present in the hydrogel the SC absorption decreased, the amounts of camphor and menthol in the SC being 50 and 190 microg/cm2, respectively (total skin accumulation was 120 and 220 microg/cm2, respectively). Such an effect was not observed for the oily solution.
Assuntos
Cânfora/farmacocinética , Mentol/farmacocinética , Absorção Cutânea , Administração Cutânea , Adulto , Anti-Infecciosos Locais/administração & dosagem , Anti-Infecciosos Locais/farmacocinética , Antipruriginosos/administração & dosagem , Antipruriginosos/farmacocinética , Cânfora/administração & dosagem , Cromatografia Gasosa , Interações Medicamentosas , Feminino , Humanos , Hidrogéis , Técnicas In Vitro , Mentol/administração & dosagem , Pessoa de Meia-Idade , Permeabilidade , Óleos de Plantas/química , Pele/metabolismo , Fatores de TempoRESUMO
(-)-Menthol, a monoterpene from Mentha species (Lamiaceae), has been shown to inhibit bone resorption in vivo by an unknown mechanism. In the present study, plasma and urine profiling in rats determined by GC/MS demonstrate that (-)-menthol is extensively metabolized, mainly by hydroxylation and carboxylation, and excreted in the urine, in part as glucuronides. In plasma, very low concentrations of (-)-menthol metabolites were detected after a single dose of (-)-menthol, whereas after repeated treatment, several times higher concentrations and long residence times were measured. In contrast, the elimination of unchanged (-)-menthol was increased by repeated treatment. (-)-Menthol, at concentrations found in plasma, did not inhibit bone resorption in cultured mouse calvaria (skull). However, the neutral metabolites of (-)-menthol, extracted from urine of rats fed with (-)-menthol, inhibited bone resorption in vitro, the concentrations being at plasma level or higher. These results suggest that not (-)-menthol itself, but one or several of its neutral metabolites inhibit the bone resorbing cells in vivo.
Assuntos
Reabsorção Óssea/sangue , Osso e Ossos/efeitos dos fármacos , Mentha , Mentol/farmacologia , Fototerapia , Extratos Vegetais/farmacologia , Administração Oral , Animais , Área Sob a Curva , Osso e Ossos/citologia , Relação Dose-Resposta a Droga , Cromatografia Gasosa-Espectrometria de Massas , Masculino , Mentol/administração & dosagem , Mentol/sangue , Mentol/metabolismo , Mentol/farmacocinética , Mentol/urina , Técnicas de Cultura de Órgãos , Extratos Vegetais/administração & dosagem , Extratos Vegetais/sangue , Extratos Vegetais/metabolismo , Extratos Vegetais/farmacocinética , Extratos Vegetais/urina , Ratos , Ratos WistarRESUMO
The matrix type transdermal drug delivery systems (TDDS) of metoprolol were prepared by film casting technique using a fabricated stainless steel film casting apparatus and characterized in vitro by drug release, skin permeation, skin irritation, and in vivo pharmacodynamic and stability studies. Four formulations were prepared that differed in the ratio of matrix forming polymers. Formulations M-1, M-2, M-3, and M-4 were composed of Eudragit RL-100 and polyvinyl acetate with the following ratios: 2:8, 4:6, 6:4, and 8:2, respectively. All the four formulations carried 10% (w/w) of metoprolol tartrate, 5% (w/w) of dibutylphthalate, and 5% (w/w) of (+/-) menthol in dichloromethane:isopropyl alcohol (80:20 v/v). Cumulative amount of drug released in 48 hr from the four formulations was 79.16%, 81.17%, 85.98%, and 95.04%. The corresponding values for cumulative amount of drug permeated for the said formulations were 59.72%, 66.52%, 77.36%, and 90.38%. On the basis of in vitro drug release and skin permeation performance, formulation M-4 was found to be better than the other three formulations and it was selected as the optimized formulation. The formulation appeared to be stable when stored at 40 degrees C and 75% RH with negligible degradation of the drug. The TDDS was found to be free of any skin irritation as suggested by skin irritation score of 1.16 (<2.00) under Draize score test. Statistically significant reduction in mean blood pressure (p < .01) was achieved in methyl prednisolone-induced hypertensive rats on treatment with the TDDS.
Assuntos
Administração Cutânea , Antagonistas Adrenérgicos beta/administração & dosagem , Sistemas de Liberação de Medicamentos/métodos , Desenho de Fármacos , Metoprolol/administração & dosagem , 2-Propanol/química , 2-Propanol/farmacocinética , Resinas Acrílicas/administração & dosagem , Resinas Acrílicas/farmacocinética , Antagonistas Adrenérgicos beta/farmacocinética , Antagonistas Adrenérgicos beta/uso terapêutico , Animais , Dibutilftalato/química , Dibutilftalato/farmacocinética , Combinação de Medicamentos , Composição de Medicamentos/métodos , Avaliação Pré-Clínica de Medicamentos/métodos , Estabilidade de Medicamentos , Desenho de Equipamento/instrumentação , Hipertensão/induzido quimicamente , Hipertensão/tratamento farmacológico , Injeções Subcutâneas , Masculino , Mentol/química , Mentol/farmacocinética , Cloreto de Metileno/química , Cloreto de Metileno/farmacocinética , Metilprednisolona/administração & dosagem , Metilprednisolona/farmacocinética , Metoprolol/farmacocinética , Metoprolol/uso terapêutico , Ratos , Ratos Wistar , Absorção Cutânea/efeitos dos fármacos , Absorção Cutânea/fisiologia , Testes de Irritação da Pele/métodos , SolubilidadeRESUMO
The objective of this study was to prepare a transdermal delivery system (TDS) for zidovudine (AZT) with a combination of menthol and oleic acid as penetration enhancers incorporated in hydroxypropyl methylcellulose, and to evaluate ex vivo as well as in vivo permeation across rat skin. It was found that AZT in gel formulation was stable in both refrigerated as well as accelerated stability conditions for 3 months and further, the gel did not significantly retard the permeability of AZT across the skin in comparison with solution formulation. Ex vivo steady state flux of AZT across rat skin from gel was 2.26 mg cm(-2) h(-1), which is sufficient to achieve therapeutic plasma concentrations. Intravenous pharmacokinetic parameters of AZT in rats were determined and used together with ex vivo flux data to generate theoretical plasma profiles of AZT and compared with plasma concentrations achieved after application of TDS. Further, steady state plasma concentrations of drug following multiple applications of TDS were determined and good correlations between ex vivo and in vivo data were observed. In addition, the combination of penetration enhancers used at 2.5% w/w in this study proved efficient in achieving sufficient enhancement in the transdermal permeability of AZT across rat skin with reduced skin irritation potential when compared with individual penetration enhancers at higher concentrations.
Assuntos
Sistemas de Liberação de Medicamentos/métodos , Avaliação Pré-Clínica de Medicamentos/métodos , Metilcelulose/análogos & derivados , Zidovudina/administração & dosagem , Zidovudina/farmacocinética , Adjuvantes Farmacêuticos/química , Adjuvantes Farmacêuticos/farmacocinética , Administração Cutânea , Animais , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/farmacocinética , Área Sob a Curva , Géis , Derivados da Hipromelose , Injeções Intravenosas , Masculino , Mentol/química , Mentol/farmacocinética , Mentol/uso terapêutico , Metilcelulose/química , Metilcelulose/farmacocinética , Ácido Oleico/química , Ácido Oleico/farmacocinética , Ácido Oleico/uso terapêutico , Permeabilidade/efeitos dos fármacos , Veículos Farmacêuticos/química , Veículos Farmacêuticos/farmacocinética , Ratos , Ratos Sprague-Dawley , Pele/efeitos dos fármacos , Pele/ultraestrutura , Absorção Cutânea/efeitos dos fármacos , Absorção Cutânea/fisiologia , Fatores de Tempo , Zidovudina/sangueRESUMO
The significant inhibitory action of diclofenac formulated in mixed micelles of lecithin with cholate or deoxycholate was observed on the rat hind paw edema induced by carrageenan. In the primary stage, mixed micelle formulation of deoxycholate was more effective compared with that of cholate. However, in the final term, the inhibitory action was similar in both formulations. In a previous study, the flux of diclofenac was greater in the mixed micelle formulation of deoxycholate compared with that of cholate. It was suggested that the permeation rate of diclofenac through skin was proportional to the pharmacological activity. The hind paw edema was quickly inhibited when cyclic monoterpene such as d-limonene or l-menthol was included in the formulations. All the micelle formulations significantly decreased the value of AUC estimated the hind paw thickness-time profile. This suggests that the micelle formulation of cholate in addition to deoxycholate showed significant anti-inflammatory activity to hind paw edema of rats. Incorporation of d-limonene or l-menthol was more effective on the decrease of AUC. A pharmacological study revealed that micelle formulations were able to reduce the skin irritation of chemicals.
Assuntos
Administração Cutânea , Diclofenaco/farmacocinética , Composição de Medicamentos/métodos , Micelas , Monoterpenos/química , Animais , Ácidos e Sais Biliares/administração & dosagem , Ácidos e Sais Biliares/química , Disponibilidade Biológica , Transporte Biológico/fisiologia , Carragenina/administração & dosagem , Carragenina/efeitos adversos , Colatos/administração & dosagem , Colatos/farmacocinética , Cicloexenos , Ácido Desoxicólico/administração & dosagem , Ácido Desoxicólico/farmacocinética , Diclofenaco/administração & dosagem , Avaliação Pré-Clínica de Medicamentos , Edema/induzido quimicamente , Edema/metabolismo , Edema/prevenção & controle , Membro Posterior/efeitos dos fármacos , Injeções , Irritantes/efeitos adversos , Limoneno , Masculino , Mentol/administração & dosagem , Mentol/farmacocinética , Monoterpenos/administração & dosagem , Ratos , Ratos Wistar , Pele/efeitos dos fármacos , Pele/fisiopatologia , Absorção Cutânea/efeitos dos fármacos , Terpenos/administração & dosagem , Terpenos/farmacocinéticaRESUMO
Enteric coating of peppermint oil/caraway oil capsules avoids subjective discomfort to the patient caused by gastroesophageal reflux. In order to confirm bioequivalence of an enteric coated formulation containing peppermint oil and caraway oil (CAS 277309-55-4, Enteroplant) and an immediate release formulation of both oils, the pharmacokinetics of menthol and carvone after oral administration of the two formulations were studied in a randomized, two-period cross-over study in 16 healthy male volunteers. The subjects received 180 mg peppermint oil and 100 mg caraway oil, once as 2 enteric coated capsules of the fixed enteric coated combination preparation containing 90 mg peppermint oil (WS 1340) and 50 mg caraway oil (WS 1520) each (test) and once in the form of 5 capsules of an immediate release formulation (reference) containing 36 mg peppermint (WS 1340) oil and 20 mg caraway oil (WS 1520) each. The capsules were taken with 250 ml water after a 10 h fast. Both substances were determined in plasma by GC/MS after extraction. The limit of quantification was 10 ng/ml for menthol and 0.5 ng/ml for carvone. The mean maximum plasma levels for menthol were 1196 ng/ml after administration of the test medication and 1492 ng/ml after administration of the reference medication. The bioavailability with respect to the AUC was comparable after administration of test and reference preparation, the 90% confidence interval was 97 to 105%. As expected, there were considerable differences for Tmax. After application of the enteric coated form the maximum concentration was reached significantly later (3.0 h vs. 1.7 h) compared to the immediate release capsule. Corresponding data were also calculated for carvone. After application of the test medication the maxima of 14 ng/ml for both formulations were reached later (2.5 h vs. 1.3 h). The 90% confidence interval of the AUC for carvone was 79 to 119% and therefore slightly outside the acceptable range for bioequivalence of 80 to 125%. However, this fact should not be relevant, in particular since the dosage of the enteric coated capsule lies at the upper limit of the model text and positive clinical studies, also on the therapeutic equivalence of the two formulations, are available.
Assuntos
Antipruriginosos/farmacocinética , Mentol/farmacocinética , Óleos de Plantas/farmacologia , Terpenos/farmacocinética , Adulto , Antipruriginosos/efeitos adversos , Área Sob a Curva , Disponibilidade Biológica , Estudos Cross-Over , Monoterpenos Cicloexânicos , Combinação de Medicamentos , Eletrocardiografia , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Masculino , Mentha piperita , Mentol/efeitos adversos , Monoterpenos , Óleos de Plantas/efeitos adversos , Comprimidos com Revestimento Entérico , Terpenos/efeitos adversosRESUMO
The purpose of this study was to evaluate the effect of taste-masking excipients on in vitro and in vivo performance of a leuprolide metered-dose inhaler (MDI) suspension formulation. Taste-masking excipients (aspartame and menthol) were added to a leuprolide suspension MDI formulation. The leuprolide MDI formulation with the taste-masking excipients was characterized in terms of milling time, particle size distribution, dose delivery and uniformity, and drug absorption in dogs. The data were compared with a formula that did not contain taste-masking excipients. It was found that the longer milling time for the leuprolide suspension with the taste-masking excipients was required to obtain a similar particle size distribution compared with the formula without taste-masking excipients using a fluid energy mill. Although measurable differences in mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were not observed between the two formulations, the percent of particles < or = 5 microns and the actuator retention for the formula with the taste-masking excipients were significantly different from the formula without taste-masking excipients using the Marple-Miller cascade impactor. Taste-masking excipients did not show a significant effect on valve delivery and through-can dose uniformity. However, the mean ex-actuator dose was 150.4 mg for the formula with the taste-masking excipients and 162.2 mg for the reference formula, respectively, indicating a significant difference. In tracheostomized dogs, both formulations showed comparable pharmacokinetic parameters including Cmax, Tmax, AUC0-12 and bioavailability (F%), indicating that the taste-masking excipients do not have an effect on lung absorption of leuprolide acetate. Therefore, inclusion of taste-masking excipients in the leuprolide MDI suspension formulation showed a significant impact on drug micronization, exactuator dose, and particle deposition pattern. Mechanistically, the unfavorable performance of leuprolide MDI in the presence of taste-masking excipients could be due to modification of the properties of the suspension itself and alteration of propellant evaporation following actuation.
Assuntos
Sistemas de Liberação de Medicamentos/instrumentação , Excipientes/administração & dosagem , Leuprolida/administração & dosagem , Nebulizadores e Vaporizadores/estatística & dados numéricos , Paladar/efeitos dos fármacos , Administração por Inalação , Aerossóis , Animais , Aspartame/administração & dosagem , Aspartame/farmacocinética , Química Farmacêutica , Estudos Cross-Over , Cães , Sistemas de Liberação de Medicamentos/métodos , Avaliação Pré-Clínica de Medicamentos/instrumentação , Avaliação Pré-Clínica de Medicamentos/métodos , Excipientes/farmacocinética , Intubação Intratraqueal , Leuprolida/sangue , Leuprolida/farmacocinética , Pulmão/metabolismo , Mentol/administração & dosagem , Mentol/farmacocinética , Tamanho da Partícula , Peptídeos/administração & dosagem , Peptídeos/sangue , Peptídeos/farmacocinética , Suspensões/administração & dosagem , Suspensões/farmacocinética , Paladar/fisiologiaRESUMO
We attempted to prepare a new griseofulvin formulation for topical application using N-methyl-2-pyrrolidone (NMP). Griseofulvin dissolves poorly in both water and oil, but dissolves in NMP to a concentration of about 100 mg/ml. A soybean oil-water emulsion with soybean lecithin and NMP as emulsifier and co-solvent, respectively, was prepared using a Microfluidizer, a high-pressure homogenizer. The size of the droplets in emulsion was about 200 nm, and the emulsion was stable for over 3 months. The skin permeation of griseofulvin through Yucatan micropig skin was studied in vitro using vertical type cells under donor phase open conditions. The permeation of griseofulvin from the NMP-water mixture (0-40%) into the skin tended to increase with increasing NMP concentration, although this finding was not statistically significant. Permeation from emulsion (oil phase, 20%; NMP 10-40%) was significantly higher than that from the water-NMP mixture. Permeation from the oil-NMP mixture was highest among the formulations investigated, and permeation from emulsion under donor phase closed conditions was significantly lower than that under open conditions. We believe that the evaporation of water from the emulsion after application to the skin was an important factor in skin permeation enhancement. When the emulsion containing 3% l-menthol was applied, a sufficient skin concentration (47 microg/cm3 in dermis) was obtained.
Assuntos
Antifúngicos/administração & dosagem , Griseofulvina/administração & dosagem , Pirrolidinonas/química , Administração Tópica , Animais , Antifúngicos/farmacocinética , Antipruriginosos/farmacocinética , Emulsões , Excipientes , Griseofulvina/farmacocinética , Técnicas In Vitro , Mentol/farmacocinética , Tamanho da Partícula , Fosfatidilcolinas , Absorção Cutânea/efeitos dos fármacos , Óleo de Soja , Suspensões , Suínos , Porco MiniaturaRESUMO
BACKGROUND: Menthol is widely used in a variety of commercial products and foods, but its clinical pharmacology is not well studied. To determine the disposition kinetics and to examine subjective and cardiovascular effects of menthol, we conducted a crossover placebo-controlled study that compared pure menthol versus placebo, along with an uncontrolled exposure to menthol in food or beverage. A novel assay for the measurement of menthol in biological fluids was also developed. METHODS: Twelve subjects were studied; each received a 100 mg l-menthol capsule, a placebo capsule, and 10 mg menthol in mint candy or mint tea on three different occasions. Plasma and urine levels of menthol and conjugated menthol (glucuronide), cardiovascular measurements, and subjective effects were measured at frequent intervals. RESULTS: Menthol was rapidly metabolized, and only menthol glucuronide could be measured in plasma or urine. The plasma half-life of menthol glucuronide averaged 56.2 minutes (95% confidence interval [CI], 51.0 to 61.5) and 42.6 minutes (95% CI, 32.5 to 52.7) in menthol capsule and mint candy/mint tea conditions, respectively (P < .05). The plasma area under the plasma concentration-time curve ratios for menthol capsule to mint candy/mint tea treatment averaged 9.2 (95% CI, 8.2 to 10.1). Urinary recovery of menthol as the glucuronide averaged 45.6 and 56.6% for menthol capsule and mint candy/tea, respectively (difference not significant). After menthol capsule dosing, the decrease in heart rate was less than the decrease after placebo administration (P < .05). Menthol reduced subjective vigor value at 30 minutes. CONCLUSIONS: We conclude that pure menthol and menthol in food or beverages have a similar systemic bioavailability and that menthol has a small cardioaccelerating effect.
Assuntos
Mentol/farmacocinética , Adulto , Área Sob a Curva , Cápsulas , Estudos Cross-Over , Método Duplo-Cego , Feminino , Meia-Vida , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Mentol/administração & dosagem , Mentol/sangue , Mentol/farmacologia , Mentol/urina , Pessoa de Meia-Idade , Valores de Referência , Chá , VoluntáriosRESUMO
Se hizo un estudio macro y micromorfológico, además del tamizaje fitoquímico y la determinación del contenido de mentol por cromatografía en capa delgada. Al mismo tiempo se realizó un estudio de conservación de la droga en condiciones de humedad y temperatura ambiental durante un año. El porcentaje de aceite esencial se mantuvo alto en todos los lotes analizados, sin verse influenciado por el tipo de secado ni por la procedencia de las muestras. El contenido de mentol determinado fue aproximadamente del 60 porciento. Los demás índices numéricos determinados se encontraron dentro de los rangos que se reportan para drogas vegetales. Se concluye que la droga puede almacenarse hasta un año en frascos de vidrio, latas compuestas y sobres de polietileno, sin que se afecte su calidad